MX2022003116A - Factor ix modificado, y composiciones, metodos y usos para la transferencia de genes a celulas, organos y tejidos. - Google Patents
Factor ix modificado, y composiciones, metodos y usos para la transferencia de genes a celulas, organos y tejidos.Info
- Publication number
- MX2022003116A MX2022003116A MX2022003116A MX2022003116A MX2022003116A MX 2022003116 A MX2022003116 A MX 2022003116A MX 2022003116 A MX2022003116 A MX 2022003116A MX 2022003116 A MX2022003116 A MX 2022003116A MX 2022003116 A MX2022003116 A MX 2022003116A
- Authority
- MX
- Mexico
- Prior art keywords
- organs
- tissues
- cells
- gene transfer
- methods
- Prior art date
Links
- 229960004222 factor ix Drugs 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 210000000056 organ Anatomy 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 102100022641 Coagulation factor IX Human genes 0.000 abstract 3
- 108010076282 Factor IX Proteins 0.000 abstract 3
- 239000013598 vector Substances 0.000 abstract 2
- 230000003612 virological effect Effects 0.000 abstract 2
- 108091026890 Coding region Proteins 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 238000013518 transcription Methods 0.000 abstract 1
- 230000035897 transcription Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
- C12N15/8645—Adeno-associated virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
La invención se refiere a una secuencia que codifica el Factor IX modificado, el casete de expresión, los vectores tales como vectores virales (por ejemplo, lenti- o adenoasociados virales), y métodos y usos de transferencia genética. En particular, se refiere a dirigir el ácido nucleico del Factor IX a las células, los tejidos u órganos para la expresión (transcripción) del Factor IX.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562183599P | 2015-06-23 | 2015-06-23 | |
US201662315453P | 2016-03-30 | 2016-03-30 | |
US201662338315P | 2016-05-18 | 2016-05-18 | |
US201662348781P | 2016-06-10 | 2016-06-10 | |
US201662349572P | 2016-06-13 | 2016-06-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022003116A true MX2022003116A (es) | 2022-04-11 |
Family
ID=57586246
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018000307A MX2018000307A (es) | 2015-06-23 | 2016-06-23 | Factor ix modificado, y composiciones, metodos y usos para la transferencia de genes a celulas, organos y tejidos. |
MX2022003116A MX2022003116A (es) | 2015-06-23 | 2018-01-08 | Factor ix modificado, y composiciones, metodos y usos para la transferencia de genes a celulas, organos y tejidos. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018000307A MX2018000307A (es) | 2015-06-23 | 2016-06-23 | Factor ix modificado, y composiciones, metodos y usos para la transferencia de genes a celulas, organos y tejidos. |
Country Status (17)
Country | Link |
---|---|
US (5) | US10799566B2 (es) |
EP (1) | EP3313991A4 (es) |
JP (3) | JP6831779B2 (es) |
KR (2) | KR102178322B1 (es) |
CN (1) | CN108138159A (es) |
AU (2) | AU2016282781A1 (es) |
BR (1) | BR112017027956A2 (es) |
CA (1) | CA2990193A1 (es) |
CO (1) | CO2018000134A2 (es) |
HK (1) | HK1252351A1 (es) |
IL (2) | IL256517B1 (es) |
MX (2) | MX2018000307A (es) |
PE (1) | PE20180675A1 (es) |
PH (1) | PH12017502424A1 (es) |
SA (1) | SA517390590B1 (es) |
SG (1) | SG10202100131WA (es) |
WO (1) | WO2016210170A1 (es) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4234687A2 (en) | 2005-04-07 | 2023-08-30 | The Trustees of the University of Pennsylvania | Method of increasing the function of an aav vector |
PL2337849T3 (pl) | 2008-09-15 | 2018-11-30 | Uniqure Biopharma B.V. | Zmutowany polipeptyd czynnika ix, jego zastosowania i sposób jego otrzymywania |
MX367100B (es) * | 2012-02-17 | 2019-08-05 | The Children´S Hospital Of Philadelphia | Composiciones del vector aav y metodos para su transferencia genetica a celulas, organos y tejidos. |
IL297919A (en) | 2013-07-22 | 2023-01-01 | Childrens Hospital Philadelphia | Modified Aav and preparations, methods and uses for gene transfer to cells, organs and tissues |
SG10202007103TA (en) | 2014-11-05 | 2020-09-29 | Voyager Therapeutics Inc | Aadc polynucleotides for the treatment of parkinson's disease |
GB201420139D0 (en) | 2014-11-12 | 2014-12-24 | Ucl Business Plc | Factor IX gene therapy |
GB201508026D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Capsid |
US10799566B2 (en) * | 2015-06-23 | 2020-10-13 | The Children's Hospital Of Philadelphia | Modified factor IX, and compositions, methods and uses for gene transfer to cells, organs, and tissues |
EP3528852A4 (en) | 2016-10-20 | 2020-06-03 | Sangamo Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR THE TREATMENT OF FABRY'S DISEASE |
CA3054711A1 (en) * | 2017-03-15 | 2018-09-20 | The University Of North Carolina At Chapel Hill | Polyploid adeno-associated virus vectors and methods of making and using the same |
US10550405B2 (en) | 2017-03-15 | 2020-02-04 | The University Of North Carolina At Chapel Hill | Rational polyploid adeno-associated virus vectors and methods of making and using the same |
EP3630974A1 (en) * | 2017-05-22 | 2020-04-08 | Baxalta Incorporated | Viral vectors encoding recombinant fix with increased expression for gene therapy of hemophilia b |
CA3064450A1 (en) * | 2017-05-31 | 2018-12-06 | The University Of North Carolina At Chapel Hill | Optimized human clotting factor ix gene expression cassettes and their use |
JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
JP2020526203A (ja) * | 2017-07-10 | 2020-08-31 | ユニキュアー アイピー ビー.ブイ. | ヒトにおけるaav遺伝子療法のための手段及び方法 |
JP2021506861A (ja) * | 2017-12-19 | 2021-02-22 | アコーオス インコーポレイテッド | 内耳への治療用抗体のaav媒介送達 |
CA3105953A1 (en) * | 2018-07-09 | 2020-01-16 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions and uses thereof |
AU2018434176A1 (en) * | 2018-07-27 | 2021-01-28 | Zentrum Für Forschungsförderung In Der Pädiatrie Gmbh | Improved concepts for the treatment of genetic disorders with high-capacity plal-generated gold nanoparticles |
US10842885B2 (en) | 2018-08-20 | 2020-11-24 | Ucl Business Ltd | Factor IX encoding nucleotides |
GB2576508A (en) * | 2018-08-20 | 2020-02-26 | Ucl Business Plc | Factor IX encoding nucleotides |
CN112739818A (zh) * | 2018-08-20 | 2021-04-30 | Ucl商业有限责任公司 | 编码因子ix的核苷酸 |
BR112021003399A2 (pt) * | 2018-08-24 | 2021-05-18 | Spark Therapeutics, Inc. | sequências de promotores otimizadas, construtos de expressão livres de íntron e métodos de uso |
KR20210090619A (ko) * | 2018-11-09 | 2021-07-20 | 제너레이션 바이오 컴퍼니 | 대칭인 변형된 역말단반복을 포함하는 변형된 폐쇄형 DNA(ceDNA) |
EP3906043A4 (en) * | 2019-01-04 | 2022-10-26 | Sangamo Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR TREATING FABRY'S DISEASE |
WO2020160303A1 (en) | 2019-02-01 | 2020-08-06 | Baxalta Incorporated | Gene therapy of hemophilia b using viral vectors encoding recombinant fix variants with increased expression |
EP3826664A4 (en) * | 2019-02-06 | 2022-10-26 | Sangamo Therapeutics, Inc. | METHOD FOR THE TREATMENT OF TYPE I MUCOPOLYSACCHARIDOSES |
CN110205297A (zh) * | 2019-05-15 | 2019-09-06 | 华北理工大学 | 一种重组脂肪干细胞及其重组方法 |
EP4022097A4 (en) * | 2019-08-29 | 2022-12-14 | Siemens Healthcare Diagnostics Inc. | REAGENTS AND METHODS FOR DETECTING ADENO-ASSOCIATED VIRUS SHEDDING |
CN111647625A (zh) * | 2019-12-25 | 2020-09-11 | 深圳三智医学科技有限公司 | 一种提高人凝血因子ix表达水平的方法 |
WO2021207415A1 (en) * | 2020-04-07 | 2021-10-14 | The Curators Of The University Of Missouri | CpG-FREE ITRs FOR AAV GENE THERAPY |
CN113817759B (zh) * | 2020-07-10 | 2023-06-02 | 南京吉迈生物技术有限公司 | 修饰的因子ix、组合物、方法及其在基因治疗中的应用 |
EP4240861A1 (en) | 2020-11-03 | 2023-09-13 | Pfizer Inc. | Methods for purification of aav vectors by anion exchange chromatography |
US20240052322A1 (en) | 2020-12-15 | 2024-02-15 | Pfizer Inc. | HILIC UPLC-MS Method For Separating and Analyzing Intact Adeno-Associated Virus Capsid Proteins |
CA3205924A1 (en) | 2020-12-23 | 2022-06-30 | Pfizer Inc. | Methods for purification of aav vectors by affinity chromatography |
WO2022208342A1 (en) | 2021-04-01 | 2022-10-06 | Pfizer Inc. | Pharmaceutical compositions containing adeno-associated viral vector |
EP4079860A1 (en) * | 2021-04-23 | 2022-10-26 | uniQure biopharma B.V. | Methods and means for the prevention and/or treatment of joint damage in hemophilia |
CN117377500A (zh) | 2021-04-26 | 2024-01-09 | 阿雷克森国际制药有限公司 | 具有改善的组织向性的腺相关病毒载体衣壳 |
EP4334454A2 (en) * | 2021-05-04 | 2024-03-13 | RegenxBio Inc. | Novel aav vectors and methods and uses thereof |
WO2022269466A1 (en) | 2021-06-22 | 2022-12-29 | Pfizer Inc. | Production of adeno-associated virus vector in insect cells |
CA3225312A1 (en) * | 2021-06-23 | 2022-12-29 | Inspirar Limited | Composition and method for treating hemophilia b |
US20230241118A1 (en) | 2021-10-20 | 2023-08-03 | University Of Rochester | Rejuvenation treatment of age-related white matter loss |
AU2022379633A1 (en) * | 2021-10-27 | 2024-04-11 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for expressing factor ix for hemophilia b therapy |
WO2023081633A1 (en) | 2021-11-02 | 2023-05-11 | University Of Rochester | Tcf7l2 mediated remyelination in the brain |
EP4198134A1 (en) | 2021-12-16 | 2023-06-21 | Genethon | Gamma-sarcoglycan gene transfer increase using modified itr sequences |
CN117247973A (zh) * | 2022-04-19 | 2023-12-19 | 康霖生物科技(杭州)有限公司 | 一种用于遗传性凝血因子缺乏病治疗的核酸构建体及其用途 |
WO2024003687A1 (en) | 2022-06-28 | 2024-01-04 | Pfizer Inc. | Nucleic acids encoding acid alpha-glucosidase (gaa) and vectors for gene therapy |
WO2024038365A1 (en) | 2022-08-16 | 2024-02-22 | Pfizer Inc. | Methods for purification of aav vectors by anion exchange chromatography |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6268213B1 (en) | 1992-06-03 | 2001-07-31 | Richard Jude Samulski | Adeno-associated virus vector and cis-acting regulatory and promoter elements capable of expressing at least one gene and method of using same for gene therapy |
WO1998010088A1 (en) | 1996-09-06 | 1998-03-12 | Trustees Of The University Of Pennsylvania | An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase |
US6156303A (en) | 1997-06-11 | 2000-12-05 | University Of Washington | Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom |
WO1999003496A1 (en) | 1997-07-21 | 1999-01-28 | The University Of North Carolina At Chapel Hill | Factor ix antihemophilic factor with increased clotting activity |
US6200560B1 (en) | 1998-10-20 | 2001-03-13 | Avigen, Inc. | Adeno-associated virus vectors for expression of factor VIII by target cells |
US6468524B1 (en) | 2000-03-22 | 2002-10-22 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | AAV4 vector and uses thereof |
US7351813B2 (en) * | 2000-06-20 | 2008-04-01 | The Board Of Trustees Of The Leland Stanford Junior University | Liver-specific gene expression cassettes, and methods of use |
EP1379281A4 (en) | 2001-03-26 | 2005-05-18 | Univ Leland Stanford Junior | HELPER-DEPENDENT ADENOVIRUS VECTOR SYSTEM AND METHOD FOR ITS USE |
US20080220015A1 (en) | 2001-08-03 | 2008-09-11 | Nokad, S.A. | Method of modulating neutralizing antibodies formation in mammals, and uses thereof in gene therapy, animal trangenesis and in functional inactivation of endogenous proteins |
CN105671005B (zh) | 2001-11-13 | 2020-09-15 | 宾夕法尼亚大学托管会 | 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法 |
AU2002360291A1 (en) | 2001-12-17 | 2003-06-30 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (aav) serotype 8 sequences |
US20040028654A1 (en) | 2002-03-22 | 2004-02-12 | Board Of Regents, The University Of Texas System | Protamine-adenoviral vector complexes and methods of use |
NZ561656A (en) | 2002-05-01 | 2009-03-31 | Univ Florida | Improved rAAV expression systems for genetic modification of specific capsid proteins |
WO2005037226A2 (en) * | 2003-10-17 | 2005-04-28 | Georgia Tech Research Corporation | Genetically engineered enteroendocrine cells for treating glucose-related metabolic disorders |
EP2438931B1 (en) | 2004-09-22 | 2013-11-13 | St. Jude Children's Research Hospital | Improved expression of factor IX in gene therapy vectors |
ATE439440T1 (de) | 2004-09-29 | 2009-08-15 | Childrens Memorial Hospital | Sirna-vermitteltes gen-silencing von alpha- synuklein |
EP4234687A2 (en) | 2005-04-07 | 2023-08-30 | The Trustees of the University of Pennsylvania | Method of increasing the function of an aav vector |
WO2007120542A2 (en) | 2006-03-30 | 2007-10-25 | The Board Of Trustees Of The Leland Stanford Junior University | Aav capsid library and aav capsid proteins |
US20090317417A1 (en) | 2006-04-28 | 2009-12-24 | The Trustees Of The University Of Pennsylvania | Modified AAV Vectors Having Reduced Capsid Immunogenicity and Use Thereof |
EP2037892B1 (en) * | 2006-06-19 | 2015-03-18 | Asklepios Biopharmaceutical, Inc. | Modified factor viii and factor ix genes and vectors for gene therapy |
ES2746907T3 (es) | 2008-04-22 | 2020-03-09 | Vib Vzw | Elementos reguladores de ácido nucleico específicos de hígado y métodos y uso de los mismos |
PL2337849T3 (pl) * | 2008-09-15 | 2018-11-30 | Uniqure Biopharma B.V. | Zmutowany polipeptyd czynnika ix, jego zastosowania i sposób jego otrzymywania |
GB0911870D0 (en) | 2009-07-08 | 2009-08-19 | Ucl Business Plc | Optimised coding sequence and promoter |
KR20120061086A (ko) * | 2009-08-18 | 2012-06-12 | 백스터 인터내셔널 인코포레이티드 | 조직 인자 경로 저해제에 대한 앱타머 및 출혈 장애 치료제로서의 이의 용도 |
EA202091105A1 (ru) | 2010-04-23 | 2020-12-30 | Юниверсити Оф Флорида Рисерч Фаундейшн, Инк. | Композиции гуанилатциклазы и способы лечения врожденного амавроза лебера типа 1 (lca1) |
ES2698203T3 (es) | 2010-04-23 | 2019-02-01 | Univ Massachusetts | Vectores de AAV que se dirigen al SNC y métodos de uso de los mismos |
KR101853405B1 (ko) | 2010-10-20 | 2018-05-02 | 주식회사 티움바이오 | 인자 ix 활성을 갖는 융합 단백질 |
JP6348064B2 (ja) | 2011-11-22 | 2018-06-27 | ザ チルドレンズ ホスピタル オブ フィラデルフィア | 効率の高いトランスジーン送達のためのウイルスベクター |
WO2013078316A1 (en) * | 2011-11-23 | 2013-05-30 | Nationwide Children's Hospital, Inc. | Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides |
LT2822577T (lt) | 2012-02-15 | 2019-03-25 | Bioverativ Therapeutics Inc. | Rekombinantiniai faktoriaus viii baltymai |
MX367100B (es) | 2012-02-17 | 2019-08-05 | The Children´S Hospital Of Philadelphia | Composiciones del vector aav y metodos para su transferencia genetica a celulas, organos y tejidos. |
WO2013158879A1 (en) | 2012-04-18 | 2013-10-24 | The Children's Hospital Of Philadelphia | Composition and methods for highly efficient gene transfer using aav capsid variants |
US9943574B2 (en) | 2012-06-27 | 2018-04-17 | Arthrogen B.V. | Combination for treating an inflammatory disorder |
GB201213117D0 (en) * | 2012-07-24 | 2012-09-05 | Ucl Business Plc | Transgene expression |
US10398787B2 (en) | 2012-10-26 | 2019-09-03 | Vrije Universiteit Brussel | Vectors for liver-directed gene therapy of hemophilia and methods and use thereof |
US20140271550A1 (en) * | 2013-03-14 | 2014-09-18 | The Trustees Of The University Of Pennsylvania | Constructs and Methods for Delivering Molecules via Viral Vectors with Blunted Innate Immune Responses |
US9700486B2 (en) * | 2013-04-24 | 2017-07-11 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
MX2016000345A (es) | 2013-07-12 | 2016-06-21 | Philadelphia Children Hospital | Vector aav y ensayo para anticuerpos neutralizantes anti-aav (virus adenoasociado). |
IL297919A (en) * | 2013-07-22 | 2023-01-01 | Childrens Hospital Philadelphia | Modified Aav and preparations, methods and uses for gene transfer to cells, organs and tissues |
GB201420139D0 (en) | 2014-11-12 | 2014-12-24 | Ucl Business Plc | Factor IX gene therapy |
CA2979495A1 (en) | 2015-03-17 | 2016-09-22 | Vrije Universiteit Brussel | Optimized liver-specific expression systems for fviii and fix |
US10799566B2 (en) * | 2015-06-23 | 2020-10-13 | The Children's Hospital Of Philadelphia | Modified factor IX, and compositions, methods and uses for gene transfer to cells, organs, and tissues |
PE20231949A1 (es) | 2015-10-30 | 2023-12-05 | Spark Therapeutics Inc | VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA |
US11191847B2 (en) | 2016-04-15 | 2021-12-07 | The Trustees Of The University Of Pennsylvania | Gene therapy for treating hemophilia B |
-
2016
- 2016-06-23 US US15/191,357 patent/US10799566B2/en active Active
- 2016-06-23 KR KR1020187002040A patent/KR102178322B1/ko active Application Filing
- 2016-06-23 EP EP16815331.0A patent/EP3313991A4/en active Pending
- 2016-06-23 IL IL256517A patent/IL256517B1/en unknown
- 2016-06-23 BR BR112017027956A patent/BR112017027956A2/pt active Search and Examination
- 2016-06-23 CN CN201680043108.6A patent/CN108138159A/zh active Pending
- 2016-06-23 WO PCT/US2016/039075 patent/WO2016210170A1/en active Application Filing
- 2016-06-23 SG SG10202100131WA patent/SG10202100131WA/en unknown
- 2016-06-23 AU AU2016282781A patent/AU2016282781A1/en not_active Abandoned
- 2016-06-23 CA CA2990193A patent/CA2990193A1/en active Pending
- 2016-06-23 PE PE2017002835A patent/PE20180675A1/es unknown
- 2016-06-23 KR KR1020207032060A patent/KR102415896B1/ko active IP Right Grant
- 2016-06-23 JP JP2017518931A patent/JP6831779B2/ja active Active
- 2016-06-23 IL IL309741A patent/IL309741A/en unknown
- 2016-06-23 MX MX2018000307A patent/MX2018000307A/es unknown
-
2017
- 2017-12-21 SA SA517390590A patent/SA517390590B1/ar unknown
- 2017-12-22 PH PH12017502424A patent/PH12017502424A1/en unknown
-
2018
- 2018-01-08 MX MX2022003116A patent/MX2022003116A/es unknown
- 2018-01-09 CO CONC2018/0000134A patent/CO2018000134A2/es unknown
- 2018-09-11 HK HK18111636.7A patent/HK1252351A1/zh unknown
-
2019
- 2019-12-09 US US16/707,984 patent/US20200129598A1/en not_active Abandoned
-
2020
- 2020-09-08 US US17/014,782 patent/US11110153B2/en active Active
-
2021
- 2021-01-29 JP JP2021012811A patent/JP7361737B2/ja active Active
- 2021-07-12 US US17/305,649 patent/US11491213B2/en active Active
-
2022
- 2022-10-28 US US18/050,982 patent/US11896652B2/en active Active
- 2022-11-09 AU AU2022268345A patent/AU2022268345A1/en active Pending
-
2023
- 2023-10-03 JP JP2023171763A patent/JP2024009857A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022003116A (es) | Factor ix modificado, y composiciones, metodos y usos para la transferencia de genes a celulas, organos y tejidos. | |
PH12020551744A1 (en) | Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues | |
PH12018502645A1 (en) | Optimized mini-dystrophin genes and expression cassettes and their use | |
GB2557123A (en) | Modified cells and methods of therapy | |
MX2017014125A (es) | Variantes de alfa-amilasa y polinucleotidos que codifican las mismas. | |
EA201992001A1 (ru) | Композиции и способы повышения экспрессии генов | |
MX2023004479A (es) | Sistema de vector multiple y sus usos. | |
GB2569733A (en) | RNA-guided nucleic acid modifying enzymes and methods of use thereof | |
MX2022003477A (es) | Medio de cultivo celular complementado con taurina y metodos de uso. | |
MX2014009975A (es) | Composiciones del vector aav y metodos para su transferencia genetica a celulas, organos y tejidos. | |
EP3741849A3 (en) | Protease variants and polynucleotides encoding same | |
MX2018005392A (es) | Acidos nucleicos modificados dirigidos a acidos nucleicos. | |
MX2017007731A (es) | Composiciones de detergente, variantes de lipasa y polinucleotidos que codifican las mismas. | |
MX2019000140A (es) | Variantes de xilanasa y polinucleotidos que las codifican. | |
MX2021010668A (es) | Proteinas de fusion de citoquinas. | |
MX2018008051A (es) | Variantes de beta-glucanasa y polinucleotidos que las codifican. | |
CA3057899A1 (en) | Diaphragm-specific nucleic acid regulatory elements and methods and use thereof | |
WO2016065349A8 (en) | Short non-coding protein regulatory rnas (sprrnas) and methods of use | |
EP3964575A3 (en) | Alpha-amylase variants and polynucleotides encoding same | |
MX2019008105A (es) | Virus. | |
EP3998341A3 (en) | Adenoviral vectors | |
EP3799878A3 (en) | Repeat variable diresidues for targeting nucleotides | |
MY190213A (en) | Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues | |
TW201612317A (en) | Gene, composition and method for improving lignocelluloses hydrolyzation |